Cambridge Investment Research Advisors
NRIX icon

Cambridge Investment Research Advisors’s Nurix Therapeutics NRIX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-29,000
Closed -$769K – 3162
2021
Q2 		$769K Hold
29,000
– – ﹤0.01% 1735
2021
Q1 		$902K Buy
+29,000
New +$1.1M ﹤0.01% 1497

Other funds holding NRIX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Cambridge Investment Research Advisors's NRIX Position: Q3 2021 in Review

Cambridge Investment Research Advisors sold out of Nurix Therapeutics (NRIX) in Q3 2021, closing a stake of 29,000 shares — an estimated $769K sold.

Cambridge Investment Research Advisors first reported a position in NRIX in Q1 2021 and held it in 2 quarters. The position peaked at $902K in Q1 2021. 113 funds tracked by Wall St. Rank hold NRIX as of Q3 2021.

  • Cambridge Investment Research Advisors reported no remaining Nurix Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 29,000 Nurix Therapeutics shares in Q3 2021, an estimated $769K.
  • Cambridge Investment Research Advisors first reported a position in Nurix Therapeutics in Q1 2021 and held it in 2 quarters.
  • Cambridge Investment Research Advisors's Nurix Therapeutics position peaked at $902K in Q1 2021.
  • 113 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2021.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2021, filed 2 Nov 2021.